Aspire Biopharma shares surge 11.11% after-hours after subsidiary to showcase BUZZ BOMB caffeine product at Health & Fitness Show 2026.

Aspire Biopharma surged 11.11% in after-hours trading following the announcement that its subsidiary, Buzz Bomb Caffeine Company, will showcase its flagship BUZZ BOMB™ product at The Health & Fitness (HFA) Show in San Diego from March 16-18, 2026. The event, attracting over 10,000 fitness professionals and 400 exhibitors, positions BUZZ BOMB™—a fast-acting 50mg caffeine dry powder stick pack—as a disruptive alternative to traditional energy drinks. The product’s rapid absorption, portability, and organic, non-GMO formulation were highlighted as key differentiators. Interim CEO Kraig Higginson emphasized the strategic value of the HFA Show for introducing the product to industry leaders, signaling potential market expansion. The news, underscoring product innovation and high-exposure marketing opportunities, directly aligns with the stock’s upward movement.